MABF3209

Anti-HPV6 Antibody, clone H6.M48

• 別名: HPV-6, Major capsid protein L1
• UNSPSCコード: 12352203

特性

• 由来生物: mouse
• 品質水準: 200
• 抗体製品の状態: purified antibody
• 抗体製品タイプ: primary antibodies
• クローン: H6.M48, monoclonal
• 分子量: calculated mol wt 55.6 kDa; observed mol wt ~N/A kDa
• 精製方法: using protein G
• 化学種の反応性: virus
• 包装: antibody small pack of 100
• テクニック: ELISA: suitable; neutralization: suitable
• アイソタイプ: IgG1κ
• タンパク質IDアクセッション番号: N/A
• UniProtアクセッション番号: P69898
• 保管温度: -10 to -25°C
• 遺伝子情報: vaccinia virus ... L1(1489370)

詳細

特異性

Clone H6.M48 is a mouse monoclonal antibody that detects HPV6. It targets an epitope within the Major capsid protein L1.

免疫原

Purified, recombinant HPV-6 L1 Virus Like-Particles.

アプリケーション

Quality Control Testing

Isotype testing: Identity Confirmation by Isotyping Test.

Isotyping Analysis: The identity of this monoclonal antibody is confirmed by isotyping test to be mouse IgG1 .

Tested Applications

Neutralizing Assay: A representative lot neutralized HPV6 in Neutralizing application (Christensen, N.D., et al. (1996). Virology. 224(2):477-86; McClements, W.L., et al. (2001). Virology. 289(2):262-8; Dias, D., et al. (2005). Clin Diagn Lab Immunol. 12(8):959-69; Smith, J.F., et al. (2008). Hum Vaccine. 4(2):134-42).

ELISA Analysis: A representative lot detected HPV6 in ELISA application (Christensen, N.D., et al. (1996). Virology. 224(2):477-86; McClements, W.L., et al. (2001). Virology. 289(2):262-8; Smith, J.F., et al. (2008). Hum Vaccin. 4(2):134-42; Brown, M.J., et al. (2014). Clin Vaccine Immunol. 21(4):587-93; Jerajani, K., et al. (2022). J Pharma Sci. 111(11):2983-2997).

ELISA Analysis: A representative lot of this antibody detected HPV6 protein in ELISA application (Data by Dr.J. Leitsch and with kind permission of ARTES Biotechnology GmbH, Germany. Recombinant HPV L1 antigens used were produced by ARTES Biotechnology GmbH).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

ターゲットの説明

Major capsid protein L1 (UniProt: P69898) is encoded by the L1 gene (Gene ID: 1489370) in Human papillomavirus type 6. The Major Capsid Protein L1 of Human papillomavirus is the primary structural protein responsible for the formation of the viral capsid, that encapsulates the genomic DNA together with Minor Capsid Protein L2. The viral capsid is composed of 360 copies of the L1 protein forming 72 pentamers, that assemble into the icosahedral capsid structure, while the L2 protein localizes along the inner surface of the virion and plays a role in capsid stabilization through interaction with the Major Capsid Protein L1. The L1 protein facilitates the attachment of the virus to the host cell by interacting with heparan sulfate proteoglycans on the cell surface, a critical step for infection. Recombinantly expressed Major Capsid Protein L1 can spontaneously assemble into Virus Like-Particles (VLPs) and were used for the development of neutralizing antibodies that show high degree of Human papillomavirus type-specificity. Based on their oncogenic potential, Human papillomaviruses (HPVs) can be classified as low-risk HPV types, (e.g.: HPV6 and HPV11, the most common serotypes) which do not cause cancer but can lead to skin and genital warts, and high-risk HPV types (e.g.: HPV 16, 18, 31, 33, 35, 45, 52, 58), that are responsible for HPV related cancers. Vaccines targeting the L1 protein, have been developed and are effective in preventing infection with the most oncogenic HPV types by inducing a robust antibody response. (Ref.: Hareza, D. A., (2022) Int. J. Mol. Sci., 23, 1818.; Christensen, N.D., et al. (1990). J Virol. 64:11, 5678-81; Christensen, N.D., et al. (1996). Virology. 224(2):477-86; Brown, M.J., et al. (2014). Clin Vaccine Immunol. 21:4, 587-93)

物理的形状

Purified mouse monoclonal antibody IgG1 in PBS without azide.

再構成

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

保管および安定性

Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

その他情報

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

安全性情報

• 保管分類コード: 12 - Non Combustible Liquids
• WGK: WGK 2
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable